Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum COSCIENS Biopharma Inc T.CSCI

Alternate Symbol(s):  CSCI

COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc., is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of unmet medical need. Its lead product, macimorelin (Macrilen; Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone... see more

TSX:CSCI - Post Discussion

View:
Post by prophetoffactz on Nov 12, 2024 11:49am

Cash

"We believe that our existing cash on hand will be sufficient to fund our anticipated operating and capital expenditure requirements for at least the next 12 months. We plan to finance our future operations and capital expenditures primarily through products sales and cash on hand. We also believe that our existing cash on hand will be sufficient to fund our anticipated operating and capital expenditure requirements beyond the next 12 months and through to 2026. We have based this estimate on assumptions that may prove to be wrong, and we could exhaust our capital resources sooner than we expect. We may also require additional capital to pursue in-licenses or acquisitions of other product candidates."
Comment by prophetoffactz on Nov 12, 2024 12:11pm
So, the AEZS/CZO merger amounted to 24-36 months of financial runway through with CZO could advance its numerous programs.2025 will hold the key milestones from the avenanthramide pill trial(safety/tolerability, preliminary efficacy) to the decision point for mass industrialization for PGX. The quality of the new President and CEO could help communicate the promise of what they have. The recent ...more  
Comment by archeo753 on Nov 12, 2024 12:18pm
Agree, all is not lost.  CSCI is in decent financial position for now.  If an exciting CEO is announced maybe will help dispell FUD.  What happened to wound healing and CoQ10?
Comment by Stinzo on Nov 12, 2024 12:36pm
The company has become less liquid then previously. There is 0 interest. 
Comment by prophetoffactz on Nov 12, 2024 12:43pm
They've never released data on the avenanthramide pill. Is it worth anything when the Phase I/IIa safety/tolerability and preliminary efficacy data is released? Theoretically a proof of principle could be established. The 100L PGX scale-up is also the decision point for mass industrialization. How compelling will the results be? They've got 50L headed towards small-scale commercialization ...more  
Comment by archeo753 on Nov 12, 2024 2:04pm
New all time low of $3.78.  Old CZO shares now worth $ .09 each.   Sad.   Market Cap 13,974,298
Comment by Stinzo on Nov 12, 2024 2:25pm
Sad is a nice way of putting it. It's pathetic.  One valuable life lesson for me.  They should just sell everything and give back wtv is left to the shareholders but clearly that won't happen and they will just keep burning everything.